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INTRODUCTION
Coichicine is an alkaloid found in the plant
Colchicurn a'utumnale (meadow saffron). Colehi-
cum was first recommended for the relief of
articular pain in the 6th Century A.D., and
centuries later legend has it that Benjamin
Franklin introduced colchicum into this country
for the treatment of gout shortly after its spec-
ificity for that disorder became known in Europe.
Colchicine was isolated from colchicum in 1820
by Pelletier and Caventou (1) and an account of
the early uses of this compound has been de-
tailed by Lits et at (2).
Pernice in 1889 was the first to observe the
effects of colchicum on cellular mitosis in his
studies on the gastrointestinal tract mucosa of
dogs (1). Later, both Lits (3) and Amoroso (4)
carefully described the cellular changes which
occur under the influence of colchicine. It re-
mained for Ludford, however, to point out that
the increase in number of cellular mitoses ob-
served following the administration of colchicine
was due to an accumulation of arrested mitoses
rather than to a stimulatory influence on cellular
division (5). The investigations of Dustin and
his associates (6), begun in 1934 and summarized
by Levine (7), led to the contention that colchi-
cine effects on cellular mitoses resulted in in-
hibition of tumor growth. More recently Levine
reviewed the action of colchicine on cellular
proliferation in both animal and plant tissues
and in human neoplasms, and discussed at length
the potentialities of colehicine therapy of tumors
in combination with X-rays or other physical
and chemical agents (7, 8).
In 1950 several previously unknown alkaloids
were isolated from Colchicum autumnale (9).
Studies with fibroblast cultures by Schar and
his associates (10) revealed that one of these
compounds, demecolcine (deacetyl-N-methyl-
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colchicine), possessed an antimitotic potency
equivalent to that of 'colchicine. The molecular
structurc of demecolcinc differs from that of
colchicinc only in the substitution of a methyl
for an acetyl radical linked to the nitrogen atom
(Fig. 1). Allegedly, the toxicity of demecolcine
for laboratory animals is somewhat less than
that of colchicine, and following early clinical
reports by Kuzell et at (11) and Colsky and co-
workers (12) demecolcinc was widely used for
the therapy of gout as well as in the treatment of
leukemia, lymphosarcoma, mycosis fungoides,
and Hodgkin's disease.
In the three patients whose case histories arc
described below, colchicine was selected for use
in the treatment of widespread psoriasis which
had become unresponsive to the usual therapeutic
methods. The choice of colchicinc was prompted
by the assumption that therapeutic results might
be similar to those observed for other potent
antimitotic agents such as the folic acid antag-
onists. The rationale for such treatment lies in
observations that have been made previously.
Kuta and Neumann (13) have linked the predilec-
tion of psoriasis for such areas as the knees and
elbows with the prior demonstration of a high
rate of cpidermal cell regeneration at these sites
(14). In studies on the Koebner phenomenon the
same workers have also claimed that for normal
skin sites in psoriatic patients the regenerative
activity of epidcrmal cells following controlled
injury is greater than for normal individuals (13).
Although the increased rate of epidermogenesis
in psoriasis may well be only a secondary man-
ifestation of the etiologic factors in this disorder,
current therapy is largely directed toward sup-
pression of cpidermal cell proliferation (15).
This can be accomplished externally with tar,
ultraviolet light, and X-ray therapy, for example,
or systemically with folic acid antagonists, colchi-
cine, and arsenic. The use of folic acid antagonists
for the treatment of psoriasis dates from the
observations of Gubner et al (16, 17), and more
recent reports on the use of these compounds
have been recorded by Rees and co-workers (18,
19) and by Edmundson and Guy (20).
For the patients with psoriasis whose case re-
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FIG. 1. Molecular structures of coichicine(left) and demecoline (deacetyl-N-methyl col-
chicine) (right).
ports follow, colchicine therapy was favored over
the use of folic acid antagonists in the expectation
that toxic side effects would be less severe. In
each ease, however, a diffuse temporary alopecia
occurred during the course of treatment. Further
investigation and discussion of this manifestation
of colchieine toxicity will be described below.
Case I
CASE REPORTS
Mrs. C. K., a 30-year old housewife, was
hospitalized at the Albert Merritt Billings Hospi-
tal for the second time on April 17, 1958, following
a recurrence of psoriasis. History revealed that the
patient had first developed psoriatic lesions over
the trunk and extremities 6 years previously, and
that chronic involvement over the scalp, arms,
hands and upper chest had persisted since that
time. Therapy with tar and salicylic acid oint-
ments together with ultraviolet light had occa-
sionally produced temporary remissions of 2—5
months duration. On her first visit to the Albert
Merritt Billings Hospital out-patient clinic in
April, 1957, the patient was hospitalized for
another recurrence of psoriatie lesions and once
more she responded well to tar ointments and
ultraviolet light therapy. Six months later, how-
ever, psoriatie lesions again appeared over the
hands, arms, and scalp. From October, 1957, to
April, 1958, these lesions slowly extended and
became more numerous over the scalp, chest, back
and extremities; in addition, all intertriginous
sites became involved. The patient was unable to
tolerate tar ointments or ultraviolet light and,
following use of ammoniated mercury, had de-
veloped cutaneous sensitivity to mercury. Be-
cause of the progressive course of her dermatitis,
hospitalization was advised in April 1958. Past
history, family history, and review of systems
were non-contributory.
Physical examination revealed innumerable
small patches and larger plaques of typical psori-
asis over approximately 80% of the skin surface.
The scalp was diffusely involved with erythema
and scaling but there was no evidence of thinning
of the hair or hair loss. The fingernails and toenails
showed pitting and subungual hyperkeratosis.
Except for moderate obesity the physical exami-
nation was otherwise negative. There were no
abnormalities in the routine laboratory data and
chest microfilm was normal.
The patient was treated locally with yellow
petrolatum for 13 days during which time no
significant change was noted in the skin lesions.
On May 1 colchicine 0.65 mgm. p.o. t.i.d. was
begun. This was continued and the daily dose
increased from 2 mgm. to 3 mgm. daily on May 9
despite moderate anorexia and diarrhea. About S
days after colchicinc was begun some fading uf
erythema and diminution of scaling were noted
in the psoriatic lesions. Subsequently, cautious
local therapy with tar and salicylic acid ointments
together with daily ultraviolet light treatments
was begun and a more rapid improvement in the
skin lesions was observed.
On May 21, twenty days after colchicinc treat-
ment had been initiated, the patient first com-
plained of some diffuse hair loss over the scalp,
and minimal hair loss over the lower extremities.
Therapy was continued unchanged, however, and
the patient was discharged from the hospital on
June 7, 1958, with her psoriasis much improved.
In the following months the patient remained
under observation and treatment in the out-pa-
tient clinic. Hair loss from the scalp continued
over a total period of almost 3 months, during
which time she lost about half of her scalp hair.
In addition, the patient complained that she had
had amenorrhea during the first three months of
colchicine therapy, and subsequently she men-
struated irregularly at 5—6 week intervals during
the next two cycles. Hair loss ceased in early
August, however, despite continued colchicinc
therapy at the same dosage level, and by Septem-
ber the patient's hair was rcgrowing thickly. Be-
cause of continued regression of the skin lesions,
colchicine was discontinued on September tenth,
and by October, 1958, the skin lesions had almost
entirely cleared with continued topical therapy.
No abnormalities were noted at any time in the
hemoglobin determinations, total white blood cell
counts, and differential white blood cell counts
obtained repeatedly throughout the period of
coichicine therapy.
Case II
Mrs. W. E., a 50-year old housewife, was hospi-
talized at Albert Merritt Billings Hospital on
May 17, 1958, for the 16th time because of exacer-
bation of long-standing psoriasis. History re-
vealed that the patient had had psoriasis since the
age of 18 years, and both psoriatic and rheumatoid
arthritis had been present since the age of 38
years. The psoriasis had been persistent and
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severe for many years, responding only partially
to the use of tar ointments and ultraviolet light
treatments. The patient was severely crippled by
her arthritis and for the past 23/b years had been
maintained on prednisolone 20—30 mgm. daily.
In the 6-week period preceding her admission to
the hospital there was a severe exacerbation of
psoriasis and some increase in arthritic pain.
With increased inflammation in the skin lesions,
the patient was now unable to tolerate either tar
ointments or ultraviolet light. Past history was
not remarkable except for a grand mal seizure 14
years prior to admission. With continued adminis-
tration of phenobarbital and dilantin no further
seizures had occurred.
Physical examination revealed a slender woman
with severe widespread psoriatic lesions over
the scalp, trunk, and extremities, and marked
arthritic deformities of the rheumatoid type.
Except for the face, the dermatitis involved the
entire skin surface. The liver was palpable 7 cm.
below the right eostal margin; it was smooth,
soft, and non-tender. There was 1+ pitting edema
over the ankles bilaterally. Physical examination
was otherwise unremarkable.
On laboratory examination the 11gb. was 11.8
Gms. Total protein was 5.8 Oms. per cent with
albumin 2.7 Gms. per cent and globulin 3.1 Gms.
per cent. Other routine and additional laboratory
data were negative. Chest microfilm was normal.
Because of the initial improvement occurring
at that time in Case I, this patient was begun on
colchicine 0.65 mgm. p.o. b.i.d. on May 17, 1958.
Yellow petrolatum was applied locally. Four days
later the colchicine dosage was increased to 0.65
mgm. p.o. t.i.d. Triamcinolone 4.0 mgm. p.o. b.i.d.
was prescribed for the arthritis. In addition the
patient received barbiturates, dilantin, and buf-
ferin. A week later her dermatitis began to im-
prove slowly, as did her joint pains. Within 2
weeks tar ointments and ultraviolet light were
well tolerated.
On June 7, 20 days after colehicine had begun,
the patient complained of some hair loss over the
scalp. Although moderate alopecia subsequently
involved the entire scalp it was most marked in
the frontal areas. Over the following 2 months
the patient lost about fl of her scalp hair. At the
time of discharge from the hospital on July 25,
1958, the patient's dermatitis was moderately
improved with diminished erythema and sealing.
Evidence of hair loss persisted in the scalp.
With continued observation of the patient, it
was noted that hair loss ceased in early August
despite the continued administration of eolchi-
cine at the same dosage level. By November the
patient stated that hair growth on the scalp was
normal again. Her psoriatic lesions remained
moderately improved at that time but further
therapeutic progress was slight.
Repeated hematological examinations in this
case showed no abnormalities.
Cese III
Mrs. A.C., a 52-year old housewife with psoria-
sis, had been hospitalized at Albert Merritt Bill-
ings Hospital for the first time following her ini-
tial clinic visit in August, 1956, for treatment of
exfoliative dermatitis. History at that time re-
vealed that 13 months previously the patient had
developed an erythematous dermatitis in the
groins which had subsequently spread to the
thighs and lower abdomen. She was treated else-
where with a variety of local applications and
received in addition 2 courses of adrenal steroid
therapy. Nonetheless, there was continuous slow
progression and spread of her dermatitis until one
month prior to admission, at which time the le-
sions became generalized over all areas of the skin
surface. Following admission to the hospital on
August 31, 1956, physical examination revealed
an exfoliative dermatitis. No other physical ab-
normalities were noted and routine laboratory
data were within normal limits. Chest film, skin
and lymph node biopsies, and bone marrow ex-
amination failed to provide any evidence of under-
lying systemic disease. For the first 6 weeks in the
hospital the patient was treated with bland oint-
ments only, but when her condition remained un-
changed, prednisolone 40 mgm. daily was begun on
September seventeenth. She improved slowly and
was subsequently discharged improved on October
10, 1956, to be followed in the out-patient clinic.
In the following 4 months treatment with tar
ointments and ultraviolet light was begun and
prednisolone dosage was slowly decreased until
the drug was discontinued on Feb. 21, 1957. By
April the patient had cleared entirely. In Aug.
1957, however, recurrent patches of typical psoria-
sis appeared over the genitalia and in the groins.
Despite continued therapy, exacerbations and
partial remissions were ultimately followed by
the appearance of widespread skin lesions over the
scalp, trunk, and extremities in October 1958. The
patient no longer tolerated tar ointments or ultra-
violet light and, following the use of ammoniated
mercury ointment, had developed cutaneous sensi-
tivity to mercury. Although eolchicine 0.65 mgm.
p.o. t.i.d. was begun in October, the patient was
forced to take the medication sporadically and
usually in smaller doses than prescribed because
of severe gastrointestinal tract symptoms of ano-
rexia, nausea, and diarrhea. Colehicine was dis-
continued 6 weeks later but with the continued
progression of psoriasis to the point where ex-
foliative dermatitis was a threat once more, colchi-
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ANIMAL EXPERIMENTS
FIG. 2A
FIG. 2B
FIG. 2. A) Rat shaved 25 days previously and
given colchicine 0.4 mgm/Kg daily for 25 days.
Note marked inhibition of spontaneous hair re-
growth. Compare with 2B. B) Control animal
shaved 25 days previously and showing normal
hair regrowth.
cine 0.65 mgm. p.o. 5 i.d. was resumed on Dec. 19,
1958. On this occasion the drug was tolerated rela-
tively well at first with the use of antispasmodics,
and clinical improvement was apparent within 10
days after medication was begun. Subsequently,
severe diarrhea supervened again and on February
9 Colcemide 2.0 mgm. p.o. t.i.d. was substituted
for colchicine. On February 20 the patient first
complained of slight hair loss from the scalp in
the frontal areas. In the next two weeks she noted
increased diffuse hair loss now involving the entire
scalp, and this has persisted for the past 3 months.
The degree of alopccia in this patient has been
mild in comparison with Cases I and II. Improve-
ment in her psoriasis has been satisfactory but
not striking.
Repeated laboratory examinations have shown
no hematological abnormalities.
Inc.
Investigations of the effects of colchicine on
hair growth were carried out in Sprague-Dawley
rats. Female animals ranging in age from 4—6
months were plucked on the right flank to induce
the anagen phase of hair growth, while at the
same time the left side was shaved with electric
clippers to observe the rate of spontaneous hair
regrowth. Colchicine was administered intra-
peritoneally to all animals in the form of a solu-
tion containing 0.5 milligram of colchicine free
base in each c.c. of sterile water. Preliminary
observations revealed that most rats would tol-
erate well the daily administration of 0.2 to 0.4
mgm/Kg of colchicine for weeks or even months
at a time, despite the late advent of progressive
ascites in some animals. Higher daily dosages
usually resulted in severe diarrhea, progressive
weight loss, and, ultimately, death of the animal.
The administration of only a single intraperi-
toneal injection of colchicine was tolerated up to
dosage levels of 1.4 mgm/Kg; animals receiving
1.1—1.4 mgm/Kg of the drug showed some diar-
rhea and weight loss for the next four to five days
but recovery was usually complete in the fol-
lowing three to four days. Higher dosages were
almost regularly fatal within 48 to 72 hours.
Daily injections of colchicine were given to 20
rats in dosages of 0.05 to 0.4 mgm/Kg for periods
ranging from 4 to 12 weeks. In untreated control
animals, the appearance of new hairs at the
plucked skin sites was noted within eight to nine
days and complete regrowth of hair from the
clipped skin sites was seen within 4 to 5 weeks.
The significant abnormality observed in the rats
receiving colchicine was a delay in spontaneous
hair regrowth. This occurred only at the higher
dosage levels (0.2—0.4 mgm/Kg) and only when
coichicine injections were begun either a few
days before or on the same day that the hair was
shaved. Injections begun 10 days after shaving
failed to inhibit hair replacement. The delay in
regrowth was so marked in some animals that
little change was noted at the shaved sites in the
first 3 to 4 weeks (Figures 2A and 2B). Bare
areas within shaved sites sometimes persisted
for as long as 12 weeks. Ultimately, however,
despite the continued administration of colchi-
cine, hair growth was resumed at the shaved
sites.
No spontaneous shedding of hair, either at
prepared or undisturbed sites, was observed in
* This material was kindly supplied by Ciba,
rat.f
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any of the treated animals. No delay in the ap-
pearance of anagen hairs at the skin surface was
seen at plucked skin sites, even with the highest
dosage level tolerated (0.4 mgm/Kg). Micro-
scopic examination of anagen hairs growing at
previously plucked skin sites failed to reveal
morphologic abnormalities in animals receiving
the highest dosages of colchicine (0.2—0.4 mgm/
Kg).
A preliminary study, currently being expanded,
was carried out next in 12 rats, while 4 additional
animals served as controls. All rats were plucked
FIG. 3. Normal anagen hair from the rat show-
ing root sheaths, keratogenous zone, and hair
matrix. X20.
on the right side, and on the 12th day after pluck-
ing the treated animals were given single intra-
peritoneal injections of colchicine ranging in
dosage from 0.8 to 1.4 mgm/Kg. Forty-eight
hours later daily microscopic examinations of
regrowing hairs by the technic of Van Scott et al
(21) were begun in all animals, and these ex-
aminations were continued for 13 days. Forty-
eight hours after the administration of colchicine
a slight constriction of the hair shaft immediately
above the matrix was noted in some hairs re-
moved from animals receiving 1.1—1.4 mgm/Kg.
Within 72 to 96 hours after the injection, morpho-
logic abnormalities in the hairs had become pro-
gressively more severe. In addition to the con-
tinued formation of a moderately to markedly
constricted hair shaft, varying degrees of hair
matrix atrophy were seen (Figs. 3—12). Over 90%
of the hairs plucked from animals receiving 1.1
to 1.4 mgm/Kg of colchicine showed these mor-
phologic changes, and many hairs displaying
mild to severe alterations were noted in the lower
dosage range (0.8 to 1.0 mgm/Kg). By the fourth
day after injection it was noted that hairs both
from previously plucked sites and from undis-
Fjo. 4. Beginning atrophy of the hair matrix.
48 hours after injection of colchicine 1.2 mgm/Kg.
X25.
turbed sites alike could be plucked with greater
ease from animals receiving 1.1 to 1.4 mgm/Kg
of colchicine than could hairs from control ani-
mals or those receiving lower dosages of the
drug. The easily plucked hairs removed from
random unprepared sites were overwhelmingly
telogen hairs and showed no morphologic changes
on microscopic examination.
As late as the 6th to 7th day after injection,
hair matrix atrophy and continued formation of
a constricted hair shaft persisted in many hairs
removed from animals receiving 0.8 to 1.1 mgm/
Kg of colchicine At the higher dosage levels
FIG. 7. Prolonged constriction of the hair shaft
FIG. 5. Atrophy of the matrix and constriction above the matrix. 1 week after injection of col-
of the hair shaft just above the matrix. 72 hours chicine 1.1 mgm/IRg. X20.
after injection of colchicine 1.1 mgm/Kg. X21.
Fro. 8. Prolonged and persistent constriction
FIG. 6. Atrophy of the matrix and constriction of the hair shaft and atrophy of the matrix. 1
of the hair shaft above the matrix. 96 hours after week after injection of colchicine 1.1 mgm/Kg.
injection of colchicine 1.4 mgm/Kg. X25. X20.
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FIG. 9. Severe constriction of the hair shaft FIG. 11. Hair showing early recovery from
and atrophy of the matrix. 1 week after injection colehicine effects with slight widening of hair shaft
of colchicine 1.1 mgm/Kg. x19. above the matrix. 8 days after injection of colchi-
cine 1.2 mgm/Kg. XiS.
FIG. 10. Constriction of the hair shaft and FIG. 12. Hair showing some recovery from col-
breakage of the hair above the matrix at the time chicine effects with widening of the hair shaft
of plucking. 1 week after injection of colehicine above the matrix. 8 days after injection of colchi-
1.2 mgm/Kg. X20. cine. 1.2 mgm/Kg. X20.
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TABLE I
Percentage at aeager hairs treni macland areas at the scalp in
psaniatia patients
% Aeaaer Hairs
I Ages Matne Females Fractal Area Panretal Area
a ege Median Mean ear ge Median Mean
[27-64 2 7 61-9774 MO I 75Tf 92
TABLE U
Percentage of onagen hairs in the
scalp at fhe time of initial hair loss in
the calchicine treated patients.
PATIENT
% Anogen Hairs
Frontal Area Parietal Area
Casel
Casel
Casefl
l9%
44%
40%
44%
64%
I
# Differential count 4 weeks after anset
af first hair lass (see test).
(1.1 to 1.4 mgm/Kg), however, the severe hair
changes had now structurally so weakened the
hairs that most of them were broken above the
hair matrix at the time of removal. By the 8th
day following colchieine injection, signs of re-
covery of hairs from the colehicine effects were
observed: the hair matrices had become less
atrophic and an increasing thickness of the newly
formed shaft above the matrix was noted in most
affected hairs. Few hairs had fully recovered,
however, prior to the onset of the catagen phase
of the hair cycle.
A study entirely similar to the one just de-
scribed was also carried out in mice of Carworth
Farms 1 strain. Thirty animals were plucked
over a site on the back and 12 days later 24 of
these were given colchicine in dosages ranging
from 2.5 to 5.5 mgm/Kg intraperitoneally. The
remaining mice served as controls. Seventeen of
the 24 animals survived the injection. At dosage
levels of 3.0 to 5.5 mgm/Kg of the drug, the
findings in the hairs were the same as those de-
scribed for the rat: almost 100% of hairs showed
profound morphologic changes of matrix atrophy
and shaft constriction in these animals. Unlike
the rats, however, all of the mice receiving colchi-
cine in dosages of 3.0 mgm/Kg or higher showed
moderate to complete hair loss at the previously
plucked sites by the fifth day following the in-
jection. The hairs spontaneously lost regularly
showed the morphologic changes already de-
scribed. Because of the much shorter period of
anagen in these animals (17 to 20 days), signs
of recovery in the hairs were minimal.
CLINIcAL INVESTIGATIONS
In order to gain further information concerning
the mechanism of colchicine alopecia in humans,
scalp hairs were plucked from our patients and
examined microscopically. Van Scott and co-
workers have observed previously that the pro-
portion of growing hairs in the occipito-parietal
region of the scalp of a normal adult varies from
63 to 91% (21). Our own observations have shown
that in adult psoriatic patients without a history
of hair loss but with involvement of those parts of
the scalp from which hairs are removed, the
proportion of anagen and telogen hairs falls
within normal limits (Table I). Inspection of
hairs from the patients receiving colchicine at
the time of initial hair loss, however, showed a
marked decrease in the number of anagen hairs
and a corresponding increase in the number of
telogen hairs taken from the frontal and parietal
areas of the scalp (Table II). Rarely, significant
morphologic abnormalities were seen in both
plucked and spontaneously shed hairs obtained
from these patients at varying intervals during
the period of active hair loss. Like the changes
seen in the rat and mouse hairs, these alterations
consisted of varying degrees of atrophy of the
hair matrix and constriction of the hair shaft
(Figs. 13—17). The characteristics of these few
abnormal hairs were also similar to those seen by
Van Scott et al (21) in the scalp hairs of patients
receiving amethopterin. Except for these occa-
sional hairs, however, all remaining hairs ob-
served in the colchieine-treated patients failed to
show detectable morphologic changes.
In one of the patients (Case III) hairs spon-
taneously shed from the scalp were collected and
examined on several occasions. These were pre-
dominantly club hairs (99—95%) and morpho-
logically abnormal anagen hairs were seen only
rarely.
Despite continued administration of eolchi-
cine at the same dosage levels over periods of 5
months or more, the first two patients noted
cessation of hair loss within 23' to 3 months
after initiation of treatment. On re-examination
4 to 6 weeks later hair regrowth was found to be
proceeding normally in both cases. In the 3rd
FIG. 13. Normal human anagen hair without FIG. 15. Marked atrophy of the hair matrix.
root sheaths. X60. Patient had taken colchicine 3.2 mgrn. daily for 6
weeks, then colcemide 6 mgm. daily for 7 weeks.
X45.
FIG. 14. Moderate atrophy of the hair matrix. FIG. 16. Bending of hair shaft at constriction
Patient had been taking colchicine 3.2 mgrn. daily site. Patient had taken coichicine and colcemide
for 4 weeks. X85. for 11 weeks. X80.
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FIG. 17. Constrictioii of hair shaft. Patient had
taken coichicine and colcemide for 11 weeks. X120.
TABLE
Percentage of onagen hairs in the scalp
4 weeks (case I) and 9 weeks (cose)
after cessation of hair loss.
0/, Anoen Hoirs
PATIENT Frontal Area Porietol Area
Case! 91% 85%
CoseIt 63% 82%
patient some hair loss continues at the present
time, 3 months after onset.
Re-examination of scalp hairs from Cases I
and II within 2 months after the alopecia had
subsided revealed normal percentages of anagen
and telogen hairs in both the frontal and parietal
areas despite continued colchicine therapy (Table
III).
DISCUSSION
Hair loss in patients following the administra-
tion of coichicine or its derivatives has been re-
corded many times in the medical literature (22—
32). Furthermore, most of these reports are in
close agreement regarding the clinical character-
istics of coichicine alopecia. The hair loss is
diffuse, not patterned, and is seen most commonly
in the scalp where it may be slight, moderate, or
severe enough to produce almost total defiuvium.
Occasionally extensive hair loss also affects the
bearded area in the male, but alopecia over the
extremities is uncommon and usually mild. The
relationship of hair loss to the amount of coichi-
cine given reveals that alopecia has followed a
wide dosage range, although from many reports
it is not possible to compute the dosage precisely.
In one patient, who had not received colchicine
or demecolcine for 31 months previously, as
little as 10.0 mgm. of demecolcine given over a
few hours period of time produced severe alopecia
14 days later (30). Another patient who received
5 intramuscular injections of colchicine for a
total dose of only 21.0 mgm. noted alopecia 20
days after the first injection (22). In most of the
other patients alopecia followed colchicine or
demecolcine in dosages ranging from 36.0 to
150.0 mgm. In one case, however, hair loss oc-
curred only following the continuous administra-
tion of demccoleine in a total dosage exceeding
450.0 mgm. over a period of 4 months (26).
Loss of hair occurs most frequently after rela-
tively large doses of colchicine and is usually
first noted 2 to 3 weeks after initial administration
of the drug. This time interval may be consider-
ably longer, particularly in patients receiving
small doses of colchicine which are then pro-
gressively increased, or in those receiving colchi-
cine intermittently at varying dosage levels.
Hair loss in any area of involvement persists for
periods of 2 or 3 weeks to 3 months, and is regu-
larly reversible
It may be presumed that colehicine alopecia
is related in some way to the antimitotic property
of the drug. In animal cells in general this phar-
macologic effect is manifested by an arrest of
nuclear division in the stage of metaphase. With
somewhat higher tissue concentrations of colchi-
cine nuclear pyknosis, disappearance of the nu-
clear membrane, and complete nuclear disinte-
gration may accompany the mitotic inhibition
(8). In the skin such colchicine effects have been
observed histologically in specimens obtained
from patients receiving intravenous coichicine for
inoperable carcinoma (33). King and Sullivan
(34) found also that topical eolchicine applied
for the treatment of condyloma acuminatum pro-
a
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duced marked cellular degenerative changes simi-
lar to those observed following local treatment
with podophyllin.
Antimitotic agents in general apparently pro-
duce hair loss by inhibiting proliferation of the
epithelial hair bulb cells. The clinical result is a
diffuse, usually reversible alopecia which is always
most striking on the scalp because of the rela-
tively high proportion of anagen hairs in that
region. Other hair-bearing sites, however, may
he involved to a lesser degree. Among compounds
presumed to interfere with hair growth in this
manner are the folic acid antagonists, nitrogen
mustard, and heparin and heparinoids. The sub-
ject of temporary alopecia from antimitotic
agents has been recently reviewed by Flesch
(35).
The striking effects of colchicine on cellular
mitosis suggest that this drug, too, produces a
temporary diffuse alopecia by interfering with
cellular proliferation within the hair matrix.
de Harven (36), working with rats, has shown
pronounced mitotic arrest in the hair matrix
cells 5—6 hours after a single dose of demecolcine.
Interestingly, he also showed a potentiation of
colchicine effects when these studies were carried
out in adrenalectomized rats, while ACTH and
cortisone produced some inhibition of colchicine
action in normal and adrenalectomized animals
respectively. Since colchicine would exert its
antimitotic effects only on anagen hairs, inter-
ference with its action by adrenal steroids may
be explained by the ability of these hormones to
slow the initiation of hair growth (37).
The precise mechanism by which colehicine
induces reversible alopecia in humans remains
to be explained. The animal experiments have
shown that in rats and mice receiving a single
large dose of colchicine intraperitoneally, anagen
hairs show severe morphologic disturbances of
matrix atrophy and shaft constriction, and that
spontaneous loss of these hairs from the follicles
may follow. These changes are continuous over a
period of several days, presumably reflecting
prolonged action and relatively slow excretion
of the drug. Analogous morphologic changes were
also seen in occasional hairs obtained from the
colchicine-treated patients. It is not difficult to
imagine, then, that in patients receiving large
dosages of colchicine over a short period of time
(as by intravenous administration, for example)
subsequent hair loss may be due to severe struc-
tural changes in the hair and hair breakage. It is
obvious that for the patients reported here, how-
ever, the overwhelming preponderance of normal
hairs requires alternative explanations for the
alopecia.
Two striking features of the alopecia, namely,
the high proportion of club hairs among the shed
hairs and the delay of 3 weeks or longer between
initiation of treatment and the first loss of hair
suggest a direct effect on the hair cycle. One may
postulate that colchicine abruptly induces
catagen with or without subsequent conversion
to telogen and that this is followed by rapid loss
of hairs from the follicles. Continuing hair loss
may be the result of different response rates of
anagen hairs to catagen conversion or varying
rates of loss of newly formed club hairs.
On the other hand, the large number of telogen
hairs observed in the differential counts could be
interpreted as indicating hair loss confined to
anagen hairs, perhaps initiated by morphologic
changes in the hair or root sheaths too subtle for
detection by the technic used. Degenerative
changes in the internal root sheath have pre-
viously been found histologically in patients re-
ceiving colchicine (33).
It seems entirely possible, then, that colchicine
alopecia may entail a broad spectrum of changes
affecting the hairs and hair growth, and that the
predominant effect may depend in good part on
the dosage of the drug and the time period during
which it is administered.
Whatever basic mechanisms may be involved
here, the ultimate cessation of hair loss despite
continued administration of colchicine raises the
question of whether an escape from mitotic in-
hibition eventually occurs in hair matrix cells.
Thereafter, at any rate, normal hair growth is
resumed and normal percentages of anagen and
telogen hairs are found.
coLcHIcJNE TREATMENT IN P5ORIA5IS
Finally, a few brief comments are in order on
the evaluation of colchicine therapy for psoriasis.
It is obviously impossible to render a firm im-
pression based only on the observation of 3
patients. In each case, however, there was
moderate improvement beginning within a week
and continuing over a period of one to three weeks
during which time the patients received, in addi-
tion, only petrolatum for topical use. At the time
treatment was begun all patients showed involve-
ment over at least 80% of the body surface. With
the continuous appearance of new lesions there
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was a distinct threat of exfoliative dermatitis in
each case. Perhaps the most valuable aspect of
coichicine treatment in these patients was the
moderation of inflammatory changes to permit
the use of tar ointments and ultraviolet light
without the irritation formerly seen. Treatment
effects were then accelerated by combined local
and systemic treatment. Only one of the patients
(Case I) cleared completely, however, and this
patient subsequently relapsed; she is now re-
sponding well to a second course of colchicine.
It is important to emphasize that colchicine
should be used for the treatment of psoriasis
only in carefully selected patients, and that these
individuals should preferably be hospitalized.
Severe diarrhea usually accompanies the rela-
tively large doses given and this unpleasant
symptom may require the judicious use of anti-
spasmodics. Hematological side-effects of colchi-
cine or demecolcine such as agranulocytosis,
aplastic anemia, and thrombocytopenia (30) re-
quire frequent blood examinations and close ob-
servation of the patient. A further interesting
side-effect observed in Case I was a 3-month
period of amenorrhea occurring during the first
3 months of therapy. This was followed by longer-
than-normal cycles of 5—6 weeks duration. Al-
though vaginal temperatures were not recorded,
it seems likely that these changes reflected a
direct effect on the ovary through inhibition of
follicular maturation; pituitary effects could not
be ruled out, however. It is of interest that in-
hibition of spermatogenesis has been observed
previously from the use of demecolcine (38).
Coichicine therapy should be reserved only for
those patients with the most severe and unre-
mitting forms of psoriasis who remain unre-
sponsive to all other accepted forms of treat-
ment. The pronounced antimitotic effects which
may occur in the hematopoetic system and,
perhaps, in germinal epithelium prohibit the use
of this drug in children and, generally, in adults
in the procreative age groups.
SUMMARY
1) The clinical characteristics of colchicine
alopecia in three patients have been described,
and the literature concerning hair loss from col-
chicine has been briefly reviewed.
2) Laboratory investigations of the effects of
colchicine on hair and hair growth in rats and
mice have revealed inhibition of spontaneous
hair growth and profound morphologic abnormal-
ties occurring in anagen hairs. The structural hair
changes assumed two forms: atrophy of the
matrix and reduced thickness of the hair shaft.
3) Findings in the scalp hairs of the patients
reported here have been discussed and specula-
tions concerning the pathogenesis of coichicine
alopecia have been presented.
4) The therapeutic effects of coichicine in
psoriasis have been evaluated and the conditions
under which use of this drug is warranted have
been carefully delineated.
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DISCUSSION
DR. EUGENE J. VAN Scon (Bethesda, Md.):
One perhaps might expect colchicine to affect the
growth of hair by bringing about the telogen
phase of the growth cycle, as Dr. Malkinson and
his associates have shown in the mouse. In the
human this effect would seem to occur also, but
the conversion to telogen is known to result from
other causes as well. The only reservation I have
concerning colchicine causing conversion of hair
to tebogen in humans is the fact that in patients
who have psoriasis of the scalp, as well as in
generally ill patients, we have observed large
numbers of telogen hairs in the absence of any
therapy. In colchicine-treated patients then is
telogen due to the specific action of the colchicine
or to more general toxic effects comparable to
those iD other toxic conditions?
DR. PETER FLE5CH (Philadelphia, Penna.)
The escape of the hair from colchiCine after con-
tinued treatment is not restricted to colchieine
alone. It has been described for folic acid antag-
onists in animals and human beings and it occurs
with heparin as well. This very interesting phe-
nomenon ought to be studied, if possible. Why
should the hair be sensitive to these agents only
in the beginning and later on become immune to
their action?
DR. FREDERICK D. MALKIN5ON (in closing):
I would like to thank the discussers.
I agree with Dr. Van Scott's reservations about
a substance having a direct effect on the hair
cycle. Nonetheless on the basis of our findings for
eolehicine so far this assumption seems reason-
able. As far as toxicity is concerned, it was not
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clear to me whether Dr. Van Scott was referring
to toxicity from psoriasis or from the drug. Sig-
nificant hair loss is seldom seen in psoriasis and
certainly there is no evidence that psoriasis is
accompanied by toxic effects which would throw
the hair into the telogen phase of growth. We
have all seen occasional patients with psoriasis
who have hair loss, but usually these are patients
who have gone into exfoliative dermatitis.
Regarding a toxic effect from the drug, I think
enough cases have been seen now where the
effects of colchicinc are greatest in those tissues
or organs showing the highest rate of mitotic cell
turnover to indicate that the antimitotic action
is the significant one. I am referring to effects on
hair matrix cells producing alopecia, and on
spermatozoa with resultant oligospermia.
